Article

Applied Clinical Trials

MedSource Expands Footprint, Adds New Service Line

MedSource is the Houston-based clinical research organization that has seen a number of growth-related milestones in the past year including its new service offering. With this in place, the new service line will be accompanied by a new department as well that will allow MedSource to provide their expertise throughought the whole drug development process.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Vertex’s Selective NaV1.8 Inhibitor Falls Short in Acute Pain Clinical Trial
August 5th 2025

Vertex’s Selective NaV1.8 Inhibitor Falls Short in Acute Pain Clinical Trial

Don Tracy, Associate Editor
Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit over placebo in post-bunionectomy surgical pain relief.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 5th 2025

ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials

Applied Clinical Trials Editorial Staff
In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
© Pixel-Shot - © Pixel-Shot - stock.adobe.com
August 5th 2025

Roche Reports Five-Year Data Supporting Long-Term Durability of Susvimo in Neovascular Age-Related Macular Degeneration

Andy Studna, Senior Editor
New results from the Phase III Portal extension study show that Susvimo maintained vision and disease control over five years in neovascular AMD, with 95% of patients requiring no supplemental treatment between six-month refill intervals.
Unifying Industry to Better Understand GCP Guidance
August 5th 2025

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
© photon_photo - © photon_photo - stock.adobe.com
August 5th 2025

Clinical Trial Failure Isn’t an Inevitable Risk—It’s Insurable and Opening the Door to New Investors

Scott Foster Natalie Marquess, ARM, CIC, CRM
Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for funding and innovation.
© Dr_Microbe - © Dr_Microbe - stock.adobe.com
August 5th 2025

Monthly Ivermectin Cuts Malaria Infection by 26% in Kenyan Phase III BOHEMIA Trial

Andy Studna, Senior Editor
In the BOHEMIA study, once-monthly ivermectin over 3 months significantly reduced malaria incidence versus albendazole in children aged 5 to 15 years, supporting its role as a novel vector-control tool amid rising insecticide resistance.
© 2025 MJH Life Sciences

All rights reserved.